FSFrancesco Saccà

Francesco Saccà

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesco Saccà has a total of 919 co-authors. Here are the top co-authors by number of shared publications:

  • Alessandro Filla

    Department of Neurosciences, Reproductive and Odontostomatological Sciences (DNSRO), Federico II University, Via S. Pansini 5, Naples, Italy

    23 shared publications
  • Chiara Pane

    Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy

    19 shared publications
  • Giuseppe De Michele

    Department of Neurosciences and Reproductive and Odontostomatological Sciences Federico II University Naples Italy

    18 shared publications
  • Angela Marsili

    Neuroscience, Reproductive and Odontostomatological Sciences (NSRO) Department, Federico II University, Naples, Italy

    17 shared publications
  • Giorgia Puorro

    Neuroscience, Reproductive and Odontostomatological Sciences (NSRO) Department, Federico II University, Naples, Italy

    16 shared publications
  • Sirio Cocozza

    Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy

    13 shared publications

Latest Publications

  • Open Access

    Patient perspectives from the BEYOND Delphi panel: burden of remaining symptoms and their fluctuations, despite treatment, in patients with generalised myasthenia gravis

    by Sophie Lehnerer, Maria Bonaria Uccheddu, Diana Sufragiu, Charlotte Carpenter, Daisy Bridge, Medi Stone, Camille Chassat, Anouska Jha, Gonçalo M.C. Rodrigues, Maartje Mangelaars, et al.

    Background: Patients with generalised myasthenia gravis (gMG) can experience remaining symptoms despite treatment. Our study aimed to describe how remaining symptoms and their fluctuations may affect a person’s daily life while living with gMG. Methods: A modified-Delphi panel (two survey rounds) was conducted with adult patients with gMG ( n =20) from seven European countries (France, Germany, Italy, the Netherlands, Sweden, Switzerland, and the UK). A scientific advisory committee including two neurologists and three patient advocacy group representatives guided the study. Consensus was defined as ≥80% participants in agreement (rated 7‒9 on a 9-point Likert scale) on a particular statement. Results: Participants receiving a range of gMG treatments highlighted the personal and variable impacts of remaining symptoms in five key domains: daily activities, social life, mental wellbeing, work and education, and future plans. Across all domains, >40% of participants declared a high impact (rating 7–9 on Likert scale), with the highest proportion of patients declaring a high impact in the mental wellbeing domain (63%). Adjustments to daily activities, evening plans, working hours or even career moves, were frequently noted impacts of remaining symptoms and fluctuations. Participants also mentioned loss of independence and fears about forthcoming symptom severity as impactful. One statement reached consensus in agreement: “if my symptoms were better controlled, I would have greater freedom to do the things I enjoy and lead a more satisfying life”. Conclusions: This study is the first to investigate the specific impacts of remaining symptoms of gMG on patients’ daily lives and how fluctuations may contribute to this impact. These results demonstrate the burden of these remaining symptoms for patients, suggesting that more effective therapeutic strategies leading to more sustained disease control would likely improve patients’ daily lives.

  • Open Access

    Age and Treatment Efficacy in Myasthenia Gravis: A Systematic Review, Meta‐Analysis, and Meta‐Regression

    by Christopher Nelke, Marion Skrobol, Lukas Theissen, Francesco Sacca, Tobias Ruck

    Background: Myasthenia gravis (MG) is increasingly concentrated in older adults, and age may shift the balance of benefit and risk for MG therapies. This study seeks to evaluate the effect of age on treatment efficacy in clinical trials of MG. Methods: PubMed and Cochrane Library were searched and clinical trials enrolling adults with MG that reported the quantitative myasthenia gravis (QMG) score and the myasthenia gravis activities of daily living (MG‐ADL) scale were included. Of 2214 records identified, 18 trials met inclusion criteria. Random‐effects meta‐analysis was used to pool treatment effects, and random‐effects meta‐regression evaluated trial‐level mean baseline age as a modifier of treatment efficacy. Results: Eighteen trials published from 2017 to 2025 included 1823 participants (982 assigned to treatment and 841 to control). Pooled effects favored treatment over control for the QMG (MD −2.402; 95% CI, −3.099 to −1.706; = 60.7%) and MG‐ADL scores (MD, −1.591; 95% CI, −1.874 to −1.309; = 0.0%). In meta‐regression, higher mean trial age was associated with attenuation of treatment benefit on the QMG scale ( β per 10 years, 1.21; 95% CI, 0.02 to 2.42; p = 0.047). This effect was most pronounced for FcRn inhibitors. No association was observed for the MG‐ADL score ( β per 10 years, 0.08; 95% CI, −0.50 to 0.66; p = 0.779). Conclusions: In this meta‐analysis, older trial populations showed smaller treatment‐related improvements in the QMG but not in the MG‐ADL score. These findings suggest that age may contribute to differences in treatment effects across MG trials.

  • Open Access

    Identifying Red Flags in Myasthenia Gravis Diagnosis, Reassessment, and Myasthenic Crisis: An Italian Delphi‐Based Position Paper

    by Francesco Habetswallner, Luca Bello, Fiammetta Biasini, Bernardo Maria De Martino, Fiammetta Vanoli, Paolo E. Alboini, Giovanni Antonini, Carlo Antozzi, Valentina Damato, Vincenzo Di Stefano, et al.

    Background and Purpose: Myasthenia gravis (MG) is a complex autoimmune disorder affecting neuromuscular transmission, often leading to diagnostic and therapeutic challenges. Timely identification of “red flags” in diagnosis, therapeutic reassessment, and myasthenic crisis is crucial to optimizing patient outcomes. This Delphi‐based consensus is aimed at synthesizing expert recommendations for improving clinical practice in Italy. Methods: A scientific board of 19 MG specialists and an extended panel of 47 neuromuscular experts participated in a structured Delphi methodology. Over an 11‐month period, consensus was developed across four areas: diagnostic red flags, confirmatory instrumental examinations, therapeutic reassessment, and the continuum from exacerbation to impending myasthenic crisis or to crisis. The threshold for achieving consensus was set at ≥ 75% agreement. Results: Globally, 68 statements reached consensus. Key findings include the identification of “red flags” for suspecting MG, with fluctuating and fatigable muscle weakness serving as primary diagnostic indicators, often involving ocular, bulbar, and respiratory muscles. Instrumental tests, such as repetitive nerve stimulation and antibody assays, were deemed essential for diagnostic confirmation. Therapeutic reassessment in MG is warranted for unsatisfactory symptom control, clinically significant adverse events, new or worsening comorbidities, planning pregnancy, or neoplastic disease. Persistent fluctuations, exacerbations, or triggers like infections should prompt adjustments, aiming to optimize treatment while minimizing risks. High‐risk factors and triggers for myasthenic crises, including thymoma and infections, were identified, with arterial blood gas analysis highlighted as critical for crisis management. Conclusions: This consensus provides actionable recommendations to enhance the identification and management of MG, addressing diagnostic delays, therapy optimization, and crisis prevention. These findings aim to guide clinical practice and foster a systematic approach to managing this heterogeneous disorder.


  • Open Access

    Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA

    by Francesco Saccà, Justin Lee, Karen S. Yee, Nicholas J. Silvestri, Guido Sabatella

    Introduction Oral corticosteroids (OCSs) and nonsteroidal immunosuppressant therapies (NSISTs) remain widely used for the clinical management of patients with generalized myasthenia gravis (gMG), despite well-documented risks. Newer targeted biologic therapies have demonstrated concomitant immunosuppressant therapy reduction; however, long-term comparative real-world evidence remains limited. This retrospective, observational study compared OCS and NSIST use in patients in the USA receiving one of the following US Food and Drug Administration-approved therapies for gMG treatment: ravulizumab or eculizumab (complement protein C5 inhibitor therapies [C5ITs]) or efgartigimod (neonatal Fc receptor antagonist). Methods Patients were identified using the IQVIA PharMetrics® Plus claims database from January 1, 2015 to March 31, 2024. Eligible patients had ≥ 2 MG claims filed ≥ 30 days apart by a nonophthalmologic specialist. Treatment index date was the date of first ravulizumab, eculizumab, or efgartigimod claim. All patients assessed were continuously treated with ravulizumab, eculizumab, or efgartigimod during the 12-month follow-up period. Baseline OCS dose was estimated using claims data 3 months before the index date. Change from baseline in OCS average daily dose (ADD), OCS tapering, and NSIST use were assessed over 3-month intervals during the 12-month post-index follow-up period. Results After 12 months of continuous treatment, the C5IT cohort experienced a significantly greater mean reduction from baseline in OCS ADD compared to the efgartigimod cohort (C5IT, − 11.2 mg/day; efgartigimod, − 3.6 mg/day; P = 0.034), and fewer patients were taking OCS ADD > 30 mg/day (C5IT, 7.5%; efgartigimod, 22.2%). The percentage of patients with NSIST claims decreased by 28.3% within the first 12 months in the C5IT cohort (baseline, 55.2%; month 12, 39.6%) and remained stable in the efgartigimod cohort (baseline, 48.9%; month 12, 48.9%). Conclusion These results from US clinical practice suggest greater reductions in OCS and NSIST concomitant therapy for patients treated with ravulizumab or eculizumab compared with efgartigimod.


  • Open Access

    Correction: A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients

    by Chiara Pane, Vincenzo Di Stefano, Nunzia Cuomo, Alessio Sarnataro, Claudia Vinciguerra, Liliana Bevilacqua, Filippo Brighina, Nicasio Rini, Giorgia Puorro, Angela Marsili, et al.


  • Open Access

    The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA‐Ataxia

    by Jason W. Robertson, Isaac Adanyeguh, Benjamin Bender, Sylvia Boesch, Arturo Brunetti, Sirio Cocozza, Léo Coutinho, Andreas Deistung, Stefano Diciotti, Imis Dogan, et al.

    Background: Spinocerebellar ataxia type 2 (SCA2) is a rare, inherited neurodegenerative disease characterized by progressive deterioration in both motor coordination and cognitive function. Atrophy of the cerebellum, brainstem, and spinal cord are core features of SCA2; however, the evolution and pattern of whole‐brain atrophy in SCA2 remain unclear.Objective: We undertook a multisite, structural magnetic resonance imaging (MRI) study to comprehensively characterize the neurodegeneration profile of SCA2.Methods: Voxel‐based morphometry analyses of 110 participants with SCA2 and 128 controls were undertaken to assess groupwise differences in whole‐brain volume. Correlations with clinical severity and genotype, and cross‐sectional profiling of atrophy patterns at different disease stages, were also performed.Results: Atrophy in SCA2 versus controls was greatest (Cohen's d >2.5) in the cerebellar white matter (WM), middle cerebellar peduncle, pons, and corticospinal tract. Very large effects (d >1.5) were also evident in the superior cerebellar, inferior cerebellar, and cerebral peduncles. In the cerebellar gray matter (GM), large effects (d >0.8) were observed in areas related to both motor coordination and cognitive tasks. Strong correlations (|r| > 0.4) between volume and disease severity largely mirrored these groupwise outcomes. Stratification by disease severity exhibited a degeneration pattern beginning in the cerebellar and pontine WM in preclinical subjects; spreading to the cerebellar GM and cerebro‐cerebellar/corticospinal WM tracts; and then finally involving the thalamus, striatum, and cortex in severe stages.Conclusion: The magnitude and pattern of brain atrophy evolve over the course of SCA2, with widespread, nonuniform involvement across the brainstem, cerebellar tracts, and cerebellar cortex; and late involvement of the cerebral cortex and striatum. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Open Access

    Altered Intracerebellar Functional Connectivity in Friedreich’s Ataxia: A Graph-Theory Functional MRI Study

    by Mario Tranfa, Teresa Costabile, Giuseppe Pontillo, Alessandra Scaravilli, Chiara Pane, Arturo Brunetti, Francesco Saccà, Sirio Cocozza

    Historically, Friedreich’s Ataxia (FRDA) has been linked to a relatively preserved cerebellar cortex. Recent advances in neuroimaging have revealed altered cerebello-cerebral functional connectivity (FC), but the extent of intra-cerebellar FC changes and their impact on cognition remains unclear. This study investigates intra-cerebellar FC alterations and their cognitive implications in FRDA. In this cross-sectional, single-center study, resting-state functional MRI data from 17 patients with FRDA (average age 27.7 ± 13.6 years; F/M = 6/11) and 20 healthy controls (HC) (average age 29.4 ± 9.7 years; F/M = 9/11), all of whom underwent neuropsychological testing, were analyzed. From functional connectivity matrices, graph measures were computed at both the network and node levels using two complementary parcellations. FRDA patients exhibited decreased global efficiency (p = 0.04), nodal degree (p = 0.001) and betweenness centrality (p = 0.04) in the vermal portion of lobule VIII, along with reduced global efficiency in cerebellar regions belonging to the Control-A network (p = 0.02), one of the three subdivisions of the Frontoparietal network. Verbal memory deficits correlated with global efficiency in both the vermal portion of lobule VIII (r = 0.53, p = 0.02) and the cerebellar regions of the Control-A network (r = 0.49, p = 0.05). Graph analysis revealed regional intra-cerebellar FC changes in FRDA, marked by reduced functional centrality in cerebellar regions of the vermis and responsible for executive functions. These changes correlated with cognitive alterations, highlighting the role of the cerebellar cortex in the cognitive impairment observed in FRDA.


  • Open Access

    The Pattern and Staging of Brain Atrophy in Spinocerebellar Ataxia Type 2 (SCA2): MRI Volumetrics from ENIGMA-Ataxia

    by Jason W. Robertson, Isaac Adanyeguh, Benjamin Bender, Sylvia Boesch, Arturo Brunetti, Sirio Cocozza, Léo Coutinho, Andreas Deistung, Stefano Diciotti, Imis Dogan, et al.

    Objective: Spinocerebellar ataxia type 2 (SCA2) is a rare, inherited neurodegenerative disease characterised by progressive deterioration in both motor coordination and cognitive function. Atrophy of the cerebellum, brainstem, and spinal cord are core features of SCA2, however the evolution and pattern of whole-brain atrophy in SCA2 remain unclear. We undertook a multi-site, structural magnetic resonance imaging (MRI) study to comprehensively characterize the neurodegeneration profile of SCA2. Methods: Voxel-based morphometry analyses of 110 participants with SCA2 and 128 controls were undertaken to assess groupwise differences in whole-brain volume. Correlations with clinical severity and genotype, and cross-sectional profiling of atrophy patterns at different disease stages, were also performed. Results: Atrophy in SCA2 relative to controls was greatest (Cohen’s d >2.5) in the cerebellar white matter (WM), middle cerebellar peduncle, pons, and corticospinal tract. Very large effects ( d >1.5) were also evident in the superior cerebellar, inferior cerebellar, and cerebral peduncles. In cerebellar grey matter (GM), large effects ( d >0.8) mapped to areas related to both motor coordination and cognitive tasks. Strong correlations (| r |>0.4) between volume and disease severity largely mirrored these groupwise outcomes. Stratification by disease severity showed a degeneration pattern beginning in cerebellar and pontine WM in pre-clinical subjects; spreading to the cerebellar GM and cerebro-cerebellar/corticospinal WM tracts; then finally involving the thalamus, striatum, and cortex in severe stages. Interpretation: The magnitude and pattern of brain atrophy evolves over the course of SCA2, with widespread, non-uniform involvement across the brainstem, cerebellar tracts, and cerebellar cortex; and late involvement of the cerebral cortex and striatum.


  • Top Cited Papers
    Open Access

    A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients

    by Chiara Pane, Vincenzo Di Stefano, Nunzia Cuomo, Alessio Sarnataro, Claudia Vinciguerra, Liliana Bevilacqua, Filippo Brighina, Nicasio Rini, Giorgia Puorro, Angela Marsili, et al.

    Introduction: Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical response to both treatments in a real-life setting. Methods: We collected baseline and follow-up clinical data using the Myasthenia Gravis-Activities of Daily Living (MG-ADL), and Quantitative Myasthenia Gravis (QMG). We included 63 patients, 32 treated with eculizumab and 31 with efgartigimod. Of the efgartigimod-treated patients, 22 were anti-acetylcholine receptor antibody-positive (AChR-Ab +) and 9 were AChR-Ab- (3 MuSK-Ab + and 6 seronegative). Results: Both treatments showed similar efficacy relative to the MG-ADL scale reduction (p = 0.237). Efgartigimod had a similar effect on both AChR-Ab + and AChR-Ab- (p = 0.280). Eculizumab was superior to efgartigimod relative to the QMG score reduction for the entire dataset (p = 0.003) and was more likely to achieve a clinical response at the QMG compared to efgartigimod (OR 1.373; p = 0.016). Steroid-sparing effect was higher for eculizumab than efgartigimod ( – 16.7 vs – 5.2 mg of the baseline daily dose at follow-up; p = 0.001). Mean speed of prednisone reduction was – 13.1 mg of the daily dose for each month of follow-up for eculizumab-treated patients and – 3.2 for efgartigimod (p = 0.001). We found three serious events, all not related to treatment in the investigator’s opinion. One eculizumab-treated patient experienced a severe pneumonia and died despite treatment. Conclusions: Our study provides evidence that eculizumab and efgartigimod can be used in clinical practice to reduce disability in gMG patients. Eculizumab-treated patients had a higher QMG response and steroid sparing effect. Efgartigimod may offer a more flexible schedule due to its cyclical use, no need for vaccination, and efficacy in AChR-Ab- patients.